Taurus Asset Management’s CorMedix CRMD Stock Holding History

Taurus Asset Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-6,000	Closed	-$39K	–	94
2018 Q4	$39K	Hold	6,000	–	–	0.01%	91
2018 Q3	$29K	Hold	6,000	–	–	﹤0.01%	97
2018 Q2	$7K	Hold	6,000	–	–	﹤0.01%	97
2018 Q1	$5K	Hold	6,000	–	–	﹤0.01%	103
2017 Q4	$15K	Hold	6,000	–	–	﹤0.01%	108
2017 Q3	$16K	Hold	6,000	–	–	﹤0.01%	103
2017 Q2	$13K	Hold	6,000	–	–	﹤0.01%	98
2017 Q1	$49K	Hold	6,000	–	–	0.01%	92
2016 Q4	$46K	Sell	6,000 -5,000	-45%	-$50.6K	0.01%	88
2016 Q3	$139K	Buy	+11,000	New	+$103K	0.03%	92
2016 Q2	–	Sell	-2,977	Closed	-$39K	–	91
2016 Q1	$39K	Hold	2,977	–	–	0.01%	92
2015 Q4	$30K	Hold	2,977	–	–	0.01%	86
2015 Q3	$30K	Hold	2,977	–	–	0.01%	92
2015 Q2	$58K	Buy	+2,977	New	+$102K	0.01%	90

Other funds holding CRMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

EGI

EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Taurus Asset Management's CRMD Position: Q1 2019 in Review

Taurus Asset Management sold out of CorMedix (CRMD) in Q1 2019, closing a stake of 6,000 shares — an estimated $39K sold.

Taurus Asset Management first reported a position in CRMD in Q2 2015 and held it in 14 quarters. The position peaked at $139K in Q3 2016. 40 funds tracked by Wall St. Rank hold CRMD as of Q1 2019.

Taurus Asset Management reported no remaining CorMedix position as of Q1 2019 after selling out during the quarter.
Taurus Asset Management sold 6,000 CorMedix shares in Q1 2019, an estimated $39K.
Taurus Asset Management first reported a position in CorMedix in Q2 2015 and held it in 14 quarters.
Taurus Asset Management's CorMedix position peaked at $139K in Q3 2016.
40 funds tracked by Wall St. Rank held CorMedix as of Q1 2019.

Based on Taurus Asset Management's 13F filing for Q1 2019, filed 15 May 2019.